Skip to main content

Dr. Matthew I. Milowsky, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
30
In the NPI registry since
2006
Medicare patients seen, 2024
139

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1996Medical school: State University of New York Downstate Medical Center
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    NY license 213906

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
139
Services billed
612
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes295102
New patient office or other outpatient visit, 45-59 minutes3636
New patient office or other outpatient visit, 60-74 minutes3333
Established patient office or other outpatient visit, 40-54 minutes2017

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Orgovyx (relugolix)68
Prednisone
Other prescribers in New York, NY
68
Xtandi (enzalutamide)59
Abiraterone Acetate46
Nubeqa (darolutamide)39
Inlyta (axitinib)21
Amlodipine Besylate
Other prescribers in New York, NY
18
Welireg (belzutifan)14
Tamsulosin Hcl
Other prescribers in New York, NY
13
Cabometyx (cabozantinib s-malate)12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $122,216 in research payments for these studies, mostly to the institutions running them.

  • A phase 2 multicohort openlabel multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48ADC alone or in combination with pembrolizumab in subjects with locallyadvanced unresectable or me…
    Seagen Inc.
  • FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
    Eli Lilly and Company · Recruiting · NCT05614739
  • A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
    Pfizer Inc.
  • A phase 2 multi cohort open label multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48 adc in subjects with HER2 expressing locally advanced unresectable or metastatic urothelial car…
    Seagen Inc.
  • A phase III randomized, double-blind, multi-center study of adjuvant nivolumab versus placebo in subjects with high risk invasive urothelial carcinoma
    E.r. Squibb & Sons, L.l.c.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in New York

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 8, 2007), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1174618987. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.